Literature DB >> 6163526

Mechanism of melphalan resistance developed in vitro in human melanoma cells.

P G Parsons, F B Carter, L Morrison.   

Abstract

Melphalan resistance developed previously in a human melanoma cell line (MM253) could not be further increased. Cross-resistance was found to nitrogen mustard but not to ultraviolet light radiation. A clone of MM253 had the same drug sensitivity and heterogeneous chromosome complements as did the parent culture. The melphalan-resistant cells (MM253-12M) had 2.6-fold the D0, 1.5-fold the size, 1.3-fold the RNA content, 1.4-fold the protein content, and 2.6-fold the DNA content of the sensitive parent line. There was no evidence for activation or detoxification of melphalan by intact melanoma cells or by mouse liver microsomes competent for the activation of other drugs. Melphalan transport was similar in both cell lines, reaching a steady-state level 3 times the concentration in the medium after 2.5 min. Both lines covalently bound the same total amount of [3H]melphalan per cell, but in MM253-12M a 50% decrease in binding to DNA was almost sufficient to account for the increase in resistance. The level of melphalan-induced DNA interstrand cross-links, which were heat labile but not alkali labile, reached a maximum during the 4-hr treatment period and then declined slowly. The degree of cross-linking in MM253-12M was 50% less than that in MM253. Unlike ultraviolet light, methyl methanesulfonate, and nitrogen mustard, melphalan at equitoxic doses did not damage the DNA sufficiently to immediately inhibit DNA synthesis. Although both lines were proficient for repair of ultraviolet light and methyl methane sulfonate damage, melphalan did not induce significant levels of DNA repair synthesis and had little effect on the rate of DNA chain elongation. In MM253 cells, strand breaks were detected only at high melphalan doses; MM253-12M formed breaks more readily. This evidence suggests that the cross-linking events and that developed resistance arises from decreased susceptibility to DNA to this damage.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6163526

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine.

Authors:  V Jevtović-Todorović; T M Guenthner; V Jevtorić-Todorović
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 2.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

3.  Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia.

Authors:  Michael J Carr; James Sun; Hidde M Kroon; John T Miura; Georgia M Beasley; Norma E Farrow; Paul J Mosca; Michael C Lowe; Clara R Farley; Youngchul Kim; Syeda Mahrukh Hussnain Naqvi; Dennis A Kirichenko; Aishwarya Potdar; Hala Daou; Dean Mullen; Jeffrey M Farma; Michael A Henderson; David Speakman; Jonathan Serpell; Keith A Delman; B Mark Smithers; Brendon J Coventry; Douglas S Tyler; John F Thompson; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2020-09-11       Impact factor: 5.344

4.  Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Authors:  M J Yagi; M Zanjani; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 5.  Optimizing regional infusion treatment strategies for melanoma of the extremities.

Authors:  Andrew Coleman; Christina K Augustine; Georgia Beasley; Gretchen Sanders; Douglas Tyler
Journal:  Expert Rev Anticancer Ther       Date:  2009-11       Impact factor: 4.512

6.  Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

Authors:  J M Klaase; B B Kroon; J H Beijnen; G W van Slooten; J A van Dongen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

7.  The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.

Authors:  Z Y Wu; B M Smithers; P G Parsons; M S Roberts
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour.

Authors:  B E Miller; F R Miller; T Machemer; G H Heppner
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

9.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Induced and inherent resistance to alkylating agents in human small-cell bronchial carcinoma xenografts.

Authors:  R Berman; G G Steel
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.